Evolut explant, Y annuloplasty, and surgical aortic valve replacement: Tips and tricks
Transcatheter aortic valve replacement (TAVR) has rapidly increased in the United States with 98,504 commercial cases listed for 2022 in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy registry (Figure 1). The American Heart Association/American College of Cardiology 2022 guidelines suggest that surgical aortic valve replacement (SAVR) is still preferred for those ≤65 years of age or with a life span expected of at least 20 years. Despite the guidance provided, a recent study from the Vizien t Clinical Data Base suggests that in 2021 almost one half of patient ≤65 years of age received a TAVR.
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Marvin D. Atkins, Yuncen A. He, Michael J. Reardon Tags: Case Report Source Type: research
More News: Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Heart | Heart Valve Surgery | Study | USA Health